Back to Search
JULIE GRAFF, M.D.
M.D.
Medical Oncology Physician
NPI: 1942445952IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
MD26998(OR)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
MD26998(OR)
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
MD26998(OR)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Class of 2003
Research & Publications (20)
Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
PMID 17382720·J Urol·2007
3-trial
Targeting the eukaryotic translation initiation factor 4E for cancer therapy.
PMID 18245460·Cancer Res·2008
6-review
Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers.
PMID 17916229·J Thromb Haemost·2007
2-rct
Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
PMID 17873238·J Clin Pharmacol·2007
2-rct
Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
PMID 17474542·Int J Clin Pharmacol Ther·2007
4-observational
Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions.
PMID 16186235·J Gen Virol·2005
8-other
Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers.
PMID 16321613·Clin Pharmacol Ther·2005
3-trial
Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
PMID 15183041·Thromb Res·2004
4-observational
Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans.
PMID 12919181·Br J Clin Pharmacol·2003
3-trial
Disassociation of carbon disulfide-induced depression of flash-evoked potential peak N166 amplitude and norepinephrine levels.
PMID 12700426·Toxicol Sci·2003
7-preclinical
Importance of amino acid 216 in nonstructural protein 2B for replication of hepatitis A virus in cell culture and in vivo.
PMID 12858403·J Med Virol·2003
7-preclinical
Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma.
PMID 11901476·Expert Opin Ther Targets·2002
6-review
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression.
PMID 10644736·J Biol Chem·2000
8-other
Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression.
PMID 10827191·J Biol Chem·2000
7-preclinical
Prevalence of developmental and behavioral disorders in a pediatric hospital.
PMID 19254983·Pediatrics·2009
8-other
Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution.
PMID 19373123·Pharmacogenet Genomics·2009
8-other
eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.
PMID 19383915·Cancer Res·2009
8-other
In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography.
PMID 19503801·J Oncol·2009
8-other
Polysaccharides derived from Yamoa (Funtumia elastica) prime gammadelta T cells in vitro and enhance innate immune responses in vivo.
PMID 19671448·Int Immunopharmacol·2009
4-observational
Rotavirus NSP1 inhibits NFkappaB activation by inducing proteasome-dependent degradation of beta-TrCP: a novel mechanism of IFN antagonism.
PMID 19180189·PLoS Pathog·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3303 SW BOND AVE, 7TH FLOOR
PORTLAND, OR 97239 - Phone
- (503) 494-6594
Quick Facts
- NPI
- 1942445952
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 23
- Publications
- 20
Are you this provider?
Claim Your Profile